LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
Halozyme Therapeutics
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
YETI Holdings
YETI
Dorian LPG
LPG
US Stock MarketDetailed Quotes
TBPH Theravance Biopharma
- 9.590
- -0.270-2.74%
Close Dec 27 16:00 ET
- 9.590
- 0.0000.00%
Post 20:01 ET
471.58MMarket Cap-9.31P/E (TTM)
9.910High9.540Low121.24KVolume9.820Open9.860Pre Close1.17MTurnover0.57%Turnover RatioLossP/E (Static)49.17MShares11.71052wk High2.54P/B204.22MFloat Cap7.44052wk Low--Dividend TTM21.29MShs Float124.866Historical High--Div YieldTTM3.75%Amplitude6.100Historical Low9.622Avg Price1Lot Size
Theravance Biopharma Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 7.49%16.87M | 3.69%14.26M | 39.22%14.5M | 11.84%57.42M | 19.91%17.57M | 26.04%15.69M | 24.43%13.75M | -21.06%10.42M | -7.17%51.35M | -1.99%14.65M |
| Operating revenue | 7.49%16.87M | 3.69%14.26M | 39.22%14.5M | 11.84%57.42M | 19.91%17.57M | 26.04%15.69M | 24.43%13.75M | -21.06%10.42M | -7.17%51.35M | -1.99%14.65M |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 6.91%26.14M | -5.90%27.01M | -23.83%25.71M | -15.14%110.72M | -25.79%23.81M | -6.47%24.45M | -7.84%28.7M | -17.86%33.76M | -55.47%130.47M | -39.18%32.08M |
| Selling and administrative expenses | 4.54%16.88M | -11.53%17.06M | -12.72%16.74M | 4.51%70.1M | -7.41%15.49M | -0.83%16.14M | 18.84%19.28M | 7.52%19.18M | -32.45%67.07M | -22.23%16.73M |
| Research and development costs | 11.51%9.27M | 5.61%9.95M | -38.46%8.97M | -35.92%40.62M | -45.84%8.31M | -15.77%8.31M | -36.85%9.43M | -37.33%14.57M | -67.27%63.39M | -50.85%15.35M |
| Operating profit | -5.88%-9.28M | 14.71%-12.75M | 51.98%-11.21M | 32.64%-53.29M | 64.20%-6.24M | 36.03%-8.76M | 25.59%-14.95M | 16.35%-23.34M | 66.71%-79.12M | 53.88%-17.43M |
| Net non-operating interest income expense | -33.31%785K | -75.00%484K | -66.86%805K | 210.94%6.77M | -61.41%1.22M | -2.97%1.18M | 538.94%1.94M | 196.70%2.43M | 129.26%2.18M | 276.32%3.17M |
| Non-operating interest income | -20.77%1.42M | -54.95%1.13M | -51.86%1.43M | 6.68%9.12M | -50.38%1.85M | -35.24%1.79M | 2.62%2.5M | --2.98M | 670.51%8.55M | 1,001.18%3.72M |
| Non-operating interest expense | 3.45%630K | 13.38%644K | 14.36%629K | -63.10%2.35M | 13.27%623K | -60.58%609K | -73.42%568K | -78.11%550K | -25.48%6.37M | -74.26%550K |
| Other net income (expense) | -1.56M | -152.44%-2.95M | 82.72%-2.74M | 0 | 61.10%-1.17M | 83.12%-1.57M | 21.20%-15.87M | 0 | ||
| Special income (charges) | ---1.56M | -152.44%-2.95M | --0 | 82.72%-2.74M | --0 | --0 | 61.10%-1.17M | 83.12%-1.57M | 21.20%-15.87M | --0 |
| -Less：Restructuring and merger&acquisition | --0 | --0 | --0 | -78.63%2.74M | --0 | --0 | -61.10%1.17M | -83.12%1.57M | -36.26%12.84M | --0 |
| -Less:Impairment of capital assets | --1.56M | --2.95M | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| -Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --3.03M | --0 |
| Income before tax | -32.56%-10.05M | -7.29%-15.22M | 53.73%-10.4M | 46.92%-49.27M | 64.82%-5.02M | 52.67%-7.58M | 37.77%-14.19M | 43.42%-22.48M | 65.00%-92.82M | 75.40%-14.26M |
| Income tax | 93.56%2.65M | -10.29%1.31M | 419.49%1.26M | 65,722.22%5.92M | 116,566.67%3.49M | 1.37M | 29,260.00%1.46M | -175.38%-395K | 105.96%9K | 98.01%-3K |
| Net income | -41.88%-12.7M | -5.65%-16.53M | 47.19%-11.66M | -106.33%-55.19M | 17.87%-8.51M | -100.98%-8.95M | -91.00%-15.65M | 14.87%-22.09M | 537.32%872.13M | 67.65%-10.36M |
| Net income continuous Operations | -41.88%-12.7M | -5.65%-16.53M | 47.19%-11.66M | 40.54%-55.19M | 40.31%-8.51M | 44.14%-8.95M | 31.36%-15.65M | 45.14%-22.09M | 64.98%-92.82M | 75.34%-14.26M |
| Net income discontinuous operations | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | 1,369.96%964.96M | -84.90%3.89M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -41.88%-12.7M | -5.65%-16.53M | 47.19%-11.66M | -106.33%-55.19M | 17.87%-8.51M | -100.98%-8.95M | -91.00%-15.65M | 14.87%-22.09M | 537.32%872.13M | 67.65%-10.36M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -41.88%-12.7M | -5.65%-16.53M | 47.19%-11.66M | -106.33%-55.19M | 17.87%-8.51M | -100.98%-8.95M | -91.00%-15.65M | 14.87%-22.09M | 537.32%872.13M | 67.65%-10.36M |
| Basic earnings per share | -52.94%-0.26 | -21.43%-0.34 | 31.43%-0.24 | -108.44%-1 | -13.33%-0.17 | -101.40%-0.17 | -154.55%-0.28 | -2.94%-0.35 | 512.89%11.85 | 65.12%-0.15 |
| Diluted earnings per share | -52.94%-0.26 | -21.43%-0.34 | 31.43%-0.24 | -108.44%-1 | -13.33%-0.17 | -101.40%-0.17 | -154.55%-0.28 | -2.94%-0.35 | 512.89%11.85 | 65.12%-0.15 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |